Bailitianheng (688506.SH): The clinical trial of BL-M14D1 (DLL3 ADC) in combination therapy for extensive stage small cell lung cancer has been approved for injection.

The Zhitong Financial APP reported that Bailing Tianheng (688506.SH) announced that the company recently received the official approval and issuance of the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration (NMPA). The company's clinical trial of the innovative biopharmaceutical BL-M14D1 (DLL3 ADC) in combination therapy has been approved; the clinical trial will involve the combination of PD-1/PD-L1 monoclonal antibodies anti-angiogenic drugs chemotherapy for the treatment of extensive-stage small cell lung cancer.